PRAME as an independent biomarker for metastasis in uveal melanoma

Clinical Cancer Research

Volumn 22, Issue 5, 2016, Pages 1234-1242

  Field, Matthew G ^a   Decatur, Christina L ^a   Kurtenbach, Stefan ^a   Gezgin, Gülçin ^b   Van Der Velden, Pieter A ^b   Jager, Martine J ^b   Kozak, Kaleigh N ^a   Harbour, J William ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FRAME PROTEIN; MESSENGER RNA; TUMOR MARKER; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; PHOSPHOPROTEIN; PRAME PROTEIN, HUMAN; RNA SPLICING FACTOR; SF3B1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ARTICLE; CANCER CLASSIFICATION; CANCER SIZE; CHROMOSOME; CHROMOSOME 11Q; CHROMOSOME 1Q; CHROMOSOME 6P; CHROMOSOME 6Q; CHROMOSOME 8Q; CHROMOSOME 9Q; CHROMOSOME LOSS; CLASSIFIER; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE MARKER; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; METASTASIS; METASTASIS FREE SURVIVAL; POLYMERASE CHAIN REACTION; PRAME GENE; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; SF3B1 GENE; UVEA MELANOMA; VALIDATION STUDY; ADULT; AGED; BIOSYNTHESIS; CLASSIFICATION; DISEASE FREE SURVIVAL; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MALE; MELANOMA; MIDDLE AGED; PATHOLOGY; UVEA TUMOR;

ADULT; AGED; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BIOPSY, FINE-NEEDLE; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PHOSPHOPROTEINS; RNA SPLICING FACTORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UVEAL NEOPLASMS;

EID: 84962231578     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2071     Document Type: Article

References (35)

1. Ramaiya KJ, Harbour JW. Current management of uveal melanoma. Exp Rev Ophthalmol 2007;2:939-46.
2. Harbour JW, Chao DL. A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology 2014;121:1281-8.
3. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64:7205-9.
4. Chang SH, Worley LA, Onken MD, Harbour JW. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res 2008;18:191-200.
5. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3.
6. van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol 2014;98: 1738-43.
7. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:5230-4.
8. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
9. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-9.
10. Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 2013;45:133-5.
11. Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013;45:933-6.
12. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12:461-8.
13. Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 2012;119:1596-603.
14. Castle Biosciences Inc. [Internet]. DecisionDx-UM Summary. c2015 [cited 2014 December 10]; Available from: http://www.myuvealmelanoma. com/health-care-professionals/decisiondx-um-summary/
15. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res 2013;41:D991-5.
16. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
17. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
18. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009;19:1639-45.
19. Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods Mol Biol 2014;1102:427-40.
20. Onken MD, Worley LA, Person E, Char DH, Bowcock AM, Harbour JW. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res 2007;13:2923-7.
21. Costessi A, Mahrour N, Tijchon E, Stunnenberg R, Stoel MA, Jansen PW, et al. The tumour antigenPRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters. EMBO J 2011;30:3786-98.
22. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:313-7.
23. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on amelanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
24. Epping MT, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 2006;66:10639-42.
25. Clarke LE, Bryan Warf M, Flake DD 2nd, Hartman AR, Tahan S, Shea CR, et al. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol 2015;42:244-52.
26. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005;122:835-47.
27. Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A, et al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev 2012;31:753-61.
28. Holling TM, Bergevoet MW, Wilson L, Van Eggermond MC, Schooten E, Steenbergen RD, et al. A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. J Immunol 2007;179:5317-25.
29. Epping MT, Wang L, Plumb JA, Lieb M, Gronemeyer H, Brown R, et al. A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2007;104:17777-82.
30. Vertuani S, Dubrovska E, Levitsky V, Jager MJ, Kiessling R, Levitskaya J. Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells. Cancer Immunol Immunother 2007;56:193-204.
31. Amir AL, van der Steen DM, van Loenen MM, Hagedoorn RS, de Boer R, Kester MD, et al. PRAME-specific Allo-HLA-restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clin Cancer Res 2011;17:5615-25.
32. Nardini M, Gnesutta N, Donati G, Gatta R, Forni C, Fossati A, et al. Sequence-specific transcription factor NF-Y displays histone-like DNA binding and H2B-like ubiquitination. Cell 2013;152:132-43.
33. Silva AG, Graves HA, Guffei A, Ricca TI, Mortara RA, Jasiulionis MG, et al. Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma. Neoplasia (New York, NY) 2010;12:11-9.
34. Kilic E, Koopmans AE, Yavuzyigitoglu S, Vaarwater J, van Ijcken WF, Paridaens D, et al. SF3B1 and EIF1AXmutations in uvealmelanoma: a protective factor, or not? [abstract]. Acta Ophthalmol [Abstracts from the 2014 European Association for Vision and Eye Research Conference] 2014;92.
35. Midena E, de Belvis V, DeiTos AP, Antonini C. Isolated brain metastasis of malignant choroidal melanoma 27 years after enucleation. Arch Ophthalmol 1999;117:1553-6.